OTS193320|OTS-193320|CAS 2093401-33-1|DC Chemicals

Cas No.:	2093401-33-1
Chemical Name:	(1s,4s)-N1-(2-(5-chloro-2,4-dimethoxyphenyl)imidazo[1,2-a]pyridin-7-yl)-N4-(4-nitrobenzyl)cyclohexane-1,4-diamine
Synonyms:	OTS-193320;OTS 193320
SMILES:	[C@@H](NC1C=CN2C=C(C3=CC(Cl)=C(OC)C=C3OC)N=C2C=1)1CC[C@@H](NCC2=CC=C([N+]([O-])=O)C=C2)CC1
Formula:	C₂₈H₃₀ClN₅O₄
M.Wt:	536.029
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:	1. Vougiouklakis T, et al. Oncotarget. 2018 Aug 7;9(61):31820-31831. View Related Products by Target Histone Methyltransferase (HMTase)

Description:	OTS193320 (OTS-193320) is a potent inhibitor of protein methyltransferase SUV39H2 with IC50 of 22.2 nM; significantly reduces global H3K9 tri-methylation (H3K9me3) in breast cancer cells in vitro and induces apoptotic cell death, attenuates γ-H2AX levels in combination with doxorubicin compared with the DOX treatment alone, and causes a significant reduction in breast cancer cell viability when compared to the treatment with a single agent; causes growth suppressive effect of SUV39H2-positive A549 lung cancer cells with IC50 of 0.38 uM.
Target:	SUV39H2
References:	1. Vougiouklakis T, et al. Oncotarget. 2018 Aug 7;9(61):31820-31831. View Related Products by Target Histone Methyltransferase (HMTase)

Cat. No.	Product name	Field of application
DC73330	IHMT-337	IHMT-337 (IHMT337) is a potent, highly selective and irreversible EZH2 inhibitor, specifically inhibits the methylation at H3K27.
DC73322	DP308	DP308 is a novel and effective 53BP1 tandem Tudor domain (TTD) inhibitor, disrupts the binding between 53BP1 and H4K20me2 peptide with IC50 of 1.69 uM.
DC72540	MS8815	MS8815 is a selective enhancer of zeste homolog 2 (EZH2) PROTAC degrader. MS8815 has inhibition activity for EZH2 with an IC50 value of 8.6 nM. MS8815 can be used for the research of triple-negative breast cancer (TNBC).
DC70785	SKLB-03176	SKLB-03176 (SKLB03176) is a potent, selective, covalent EZH2 inhibitor with IC50 of 47 nM, covalently binds to the SAM pocket of EZH2.SKLB-03176 showed good inhibitory activity against mutations EZH2 Y641F, EZH2 Y641N, and EZH2A677G at 200 nM concentration.SKLB-03176 exhibited weak activity against other targets, such as 5 histone methyltransferases and more than 30 kinases, >50-fold selective for EZH2 over the highly homologous H3K27 methyltransferase EZH1 (IC50=2.45 uM).SKLB-03176 inhibited the activity of a variety of EZH2 mutants and significantly inhibited the expression of H3K27Me3 in cells.SKLB-03176 showed no cytotoxicity to normal cells.
DC70095	NSD1 inhibitor BT5	NSD1 inhibitor BT5 is a covalent, small molecule inhibitor of NSD1 histone methyltransferase with IC50 of 1.4 uM, shows no covalent binding to NSD2.
DC47616	EPZ-719	EPZ-719 is a novel and potent SETD2 inhibitor ( IC50 = 0.005 μM) with a high selectivity over other histone methyltransferases.
DC47608	EZH2-IN-2	EZH2-IN-2 is a EZH2 inhibitor extracted from patent WO2018133795A1, Compound Example 69, with an IC50 of 64 nM. EZH2-IN-2 can be used for the research of cancer or precancerous condition related to EZH2 activity.
DC46276	BRD0639	BRD0639 is a first-in-class inhibitor of the PRMT5-substrate adaptor interaction. BRD0639 is a PRMT5 binding motif (PBM)-competitive agent that can support studies of PBM dependent PRMT5 activities.
DC44514	MR837(ZINC30303842)	MR837 is an inhibitor of NSD2-PWWP1. MR837 can bind with human nuclear receptor binding SET domain protein 2 (PWWP domain).
DC28700	MAK683-CH2CH2COOH	MAK683-CH2CH2COOH binds to EED (embryonic ectoderm development protein). MAK683-CH2CH2COOH and a VHL ligand for the E3 ubiquitin ligase have been used to design PROTAC EED degrader-1 and PROTAC EED degrader-2.